- Home
- ROIV vs UHS Comparison
ROIV vs UHS Comparison
Compare ROIV & UHS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ROIV | UHS |
|---|---|---|
| Founded | 2014 | 1978 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Hospital/Nursing Management |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 14.1B | 14.4B |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | ROIV | UHS |
|---|---|---|
| Price | $21.70 | $223.29 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 8 | 12 |
| Target Price | $21.94 | ★ $232.58 |
| AVG Volume (30 Days) | ★ 6.7M | 685.9K |
| Earning Date | 11-10-2025 | 10-27-2025 |
| Dividend Yield | N/A | ★ 0.36% |
| EPS Growth | N/A | ★ 39.76 |
| EPS | N/A | ★ 21.01 |
| Revenue | $20,329,000.00 | ★ $16,992,503,000.00 |
| Revenue This Year | N/A | $10.93 |
| Revenue Next Year | $376.94 | $4.96 |
| P/E Ratio | ★ N/A | $10.59 |
| Revenue Growth | N/A | ★ 10.21 |
| 52 Week Low | $8.73 | $152.33 |
| 52 Week High | $22.45 | $246.33 |
Technical Indicators
Market Signals| Indicator | ROIV | UHS |
|---|---|---|
| Relative Strength Index (RSI) | 62.44 | 44.40 |
| Support Level | $20.14 | $219.94 |
| Resistance Level | $21.48 | $226.00 |
| Average True Range (ATR) | 0.71 | 5.52 |
| MACD | 0.00 | -2.36 |
| Stochastic Oscillator | 65.96 | 11.94 |
Price Performance
Historical ComparisonAbout ROIV Roivant Sciences Ltd.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.
About UHS Universal Health Services Inc.
Universal Health Services Inc owns and operates acute care hospitals, behavior health centers, surgical hospitals, ambulatory surgery centers, and radiation oncology centers. The firm operates in two segments: Acute Care Hospital Services and Behavioral Health Services. The company generates the majority of its revenue from the Acute Care Hospital Services segment. The Acute Care Hospital Services segment includes the firm's acute care hospitals, surgical hospitals, and surgery and oncology centers.